News

While the remarkable activity of crizotinib as treatment of patients with ROS1 fusion-positive advanced non–small cell lung cancer was confirmed in a recent systemic review and meta-analysis, the efficacy of this small molecular inhibitor remains unknown in patients with MET-altered disease.

The FDA has granted an Orphan Drug designation to CPI-613 for the treatment of soft tissue sarcoma.

The FDA has accepted the supplemental Biologics License Application for cemiplimab-rwlc and granted it Priority Review for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer with ≥50% PD-L1 expression.

In evaluating MYC rearrangement and its correlation with disease burden and prognostics in newly diagnosed multiple myeloma, a group of Mayo Clinic investigators found that the alteration is associated with high disease burden and independently prognosticates adverse outcomes in patients.

The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.

The FDA has granted approval to the FoundationOne Liquid CDx as a companion diagnostic indicated for the to identify patients who may derive benefit from treatment with 3 FDA-approved targeted therapies, including alpelisib, rucaparib, and alectinib.

The FDA granted a Priority Review designation to the supplemental Biologics License Application for trastuzumab deruxtecan as treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

During a recent tweet chat, Sara M. Tolaney, MD, MPH, joined Targeted Oncology for the discussion of a 39-year-old woman with relapsed/refractory HR-negative/HER2-positive metastatic breast cancer.

In an interview with Targeted Oncology, Masahiro Tsuboi, MD, discussed the findings for the ADAURA study, which explored the role of osimertinib as treatment of patients with early-stage EGFR-mutant non-small cell lung cancer following a complete tumor resection.

The IDH1 inhibitor olutasidenib showed a favorable safety profile in patients with relapsed/refractory acute myeloid leukemia treated in a phase 1/2 clinical trial, according to topline results.

Adagrasib demonstrated promising antitumor activity as monotherapy in patients with previously treated KRAS G12C–mutant non–small cell lung cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Historically, in gastrointestinal malignancies, chemotherapy and radiation were utilized to improve outcomes for patients. Although these treatments were effective, disease recurrence was always imminent, demonstrating a need for novel therapies.

The FDA granted approval to the FoundationOne®CDx as a companion diagnostic for the identification of NTRK fusions across all solid tumors for the approved larotrectinib.

At the International Kidney Cancer Symposium Virtual Event, the 2019 Nobel Laureate and recipients of the Kidney Cancer Association’s Andrew C. Noviak Award and the Pieter de Mulder Memorial Award will give lectures on key topics in the kidney cancer landscape on November 6 and 7.

In an interview with Targeted Oncology, Naomi Haas, MD, discussed the role of PSMA in the treatment landscape of prostate cancer and highlighted the key findings from the phase 1 chimeric antigen receptor T-cell trial in metastatic castration resistance prostate cancer.

Targeted Oncology reviews trending news online for the week of October 23, 2020, including updates in oncology and the COVID-19 pandemic.

During a Targeted Oncology Case Based Peer Perspectives event, Neeraj Agarwal, MD, discussed the case of a 57-year-old male patient with nonmetastatic castration resistant prostate cancer.

OneOncology announced the creation of OneOncology Research Network, which is a national non-exclusive clinical trial site management organization.

Driver alterations in neuregulin 1 fusions have recently come to light as a new target in patients with advanced or metastatic solid tumors. Multiple factors contribute to poor outcomes in this patients population with limited option for resolution.

The phase 3 CASSIOPEIA study met its primary end point of progression-free survival with daratumumab maintenance in newly-diagnosed multiple myeloma eligible for autologous stem cell transplant.

Looking at the pipeline for larotrectinib, it shows an accelerated course, which can be attributed to the drug’s potential to fulfill an unmet need in oncology.

Two immune systems conditions, hypogammaglobulinemia and hypocomplementemia, may be predictive of adverse outcomes in patients with diffuse large B-cell lymphoma, according to a published study.

In an interview with Targeted Oncology, Alexander Spira, MD, PhD, discussed the findings from the clinical trial evaluating amivantamab in combination with lazertinib as treatment of patients with advanced EGFR-mutant non-small cell lung cancer.

The FDA granted a Fast Track designation to the combination of ublituximab plus umbralisib for the treatment of adult patients with chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the findings for the global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.

Afatinib, an FDA-approved frontline treatment for patients with metastatic non–small cell lung cancer, has now demonstrated efficacy and tolerable safety in the second-line setting of metastatic squamous cell carcinoma of the lung

The FDA granted a Priority Review designation to adjuvant osimertinib as treatment of patients with stage IB/II/IIIA EGFR-mutant non–small cell lung cancer following a complete tumor resection with curative intent.

Several late-phase results were shared during the European Society of Medical Oncology Virtual Congress in gynecologic malignancies, but the data presented generated excitement about the number of novel options for patients after initial treatment.

In an interview with Targeted Oncology, Bradley McGregor, MD, discussed the findings from the CheckMate-9ER study of nivolumab and cabozantinib as treatment of patients with advanced renal cell carcinoma, as well as the health-related QoL data supporting the use of this combination.

Encouraging anti-tumor activity was observed with the combination of quavonlimab and pembrolizumab when given as frontline therapy to patients with advanced non–small cell lung cancer in a phase 1 study.